drugset / Trial / NCT00723528
An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of ustekinumab (CNTO 1275) compared with placebo in participants with moderate to severe plaque type psoriasis.
Timeline
- Start
- 2008-03
- Primary completion
- 2009-01
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ustekinumab | Monoclonal antibody | 45 mg | Subcutaneous |
| Comparator | Ustekinumab | Monoclonal antibody | 90 mg | Subcutaneous |